A Brief Overview of Cholinergic and Phosphodiesterase-5 Inhibitors in Diabetic Bladder Dysfunction

Area of Science:

• Urology
• Endocrinology
• Pharmacology

Background:

• Diabetic bladder dysfunction (DBD) presents diverse lower urinary tract symptoms in diabetic patients.
• Common symptoms include urinary frequency, urgency, incontinence, and incomplete bladder emptying.
• Anticholinergic medications are frequently prescribed for symptom relief.

Purpose of the Study:

• To review the pathophysiology of diabetic bladder dysfunction.
• To focus on cholinergic and phosphodiesterase inhibitors as therapeutic options for DBD.
• To identify research gaps and future directions in DBD treatment.

Main Methods:

• This study is a narrative review of existing literature.
• It examines the pathophysiology of DBD.
• It analyzes the roles of anticholinergic and phosphodiesterase 5 (PDE5) inhibitors in DBD management.

Main Results:

• Evidence suggests diabetic patients may benefit from PDE5 inhibitors.
• Anticholinergics are established treatments, but PDE5 inhibitors offer a potential alternative or adjunct therapy.
• The literature highlights gaps in understanding DBD mechanisms.

Conclusions:

• Further research is needed to fully understand DBD mechanisms.
• New research tools and models, particularly rodent models, are essential for elucidating therapeutic mechanisms.
• PDE5 inhibitors represent a promising area for future DBD treatment strategies.